A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 240 participants.
Also called NCT07796477
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 240 participants
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Registry
-
NCT07796477
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07796477. Randomized; double masking; primary purpose treatment. Start 2026-11-06 (anticipated); primary completion 2027-09-28 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin
- Condition
- T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug)
- SYH2069 Injection (group 1)
- Intervention (Drug)
- SYH2069 Injection (group 2)
- Intervention (Drug)
- SYH2069 Injection (group 3)
- Intervention (Drug)
- SYH2069 Injection (group 4)
- Intervention (Drug)
- SYH2069 Injection placebo
- Intervention (Drug)
- Tirzepatide Injection 15mg
- Lead sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07796477- Content hash
d2e86011e837f5477984345bf263c8970fad37f68824d2a71b4b7d301618c19c